Article Per Year (5 Year)
p-Index From 2021 - 2026
0.817
P-Index
This Author published in this journals
All Journal Althea Medical Journal Universa Medicina Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Nanny Natalia Mulyani Soetedjo
Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Padjadjaran, Bandung, Indonesia
Biochemistry, Genetics & Molecular Biology Education Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 7 Documents
Search

 1 
Pola Penggunaan Antidiabetes Oral Pasien Diabetes MelitusTipe 2 di Bagian Penyakit Dalam RSUD Kota Bandung Tahun 2017 Kevin Jonathan; Kuswinarti -; Nanny Natalia Mulyani Soetedjo
Cermin Dunia Kedokteran Vol 46, No 6 (2019): Diabetes Mellitus
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.462

Abstract

DM merupakan penyakit kronis seumur hidup, tidak dapat disembuhkan namun dapat dikontrol dengan intervensi farmakologis, salah satunya antidiabetes oral. Penelitian ini bertujuan untuk mengetahui pola penggunaan antidiabetes oral pada pasien rawat jalan DM tipe 2 di bagian Penyakit Dalam RSUD Kota Bandung pada Januari – Desember 2017. Penelitian ini merupakan penelitian deskriptif dengan desain penelitian potong lintang setiap bulan. Pengambilan sampel secara retrospektif dari data rekam medis pasien dengan menghitung sampel minimal menggunakan rumus Finite Population Correction. Dari 115 sampel meliputi 83 (72,2%) perempuan dan 32 (27,8%) laki-laki, antidiabetes terbanyak terapi tunggal metformin berkisar antara 25 pasien (21,7%) hingga 50 pasien (43,5%)/bulan, diikuti terapi kombinasi 2 antidiabetes metformin dan gliklazid berkisar antara 16 pasien (13,9%) hingga 22 pasein (19,1%)/bulan, dan terapi kombinasi 3 antidiabetes metformin, glikuidon, dan pioglitazon berkisar antara 1 pasien (0,9%) hingga 7 pasien (6,1%)/bulan serta metformin, gliklazid dan akarbose sebanyak 3 pasien (2,6%) hingga 6 pasien (5,2%)/bulan. Obat lain untuk komorbid DMT2 yang terbanyak adalah obat hipertensi sebanyak 57,2%.DM is a chronic disease, controlled pharmacologically, using – among others - oral antidiabetic drugs. This study aims to determine the pattern of use of oral anti-diabetics in DM type 2 outpatients in the Internal Medicine Department of Bandung City Hospital in January - December 2017. This is a descriptive cross-sectional monthly study. Sampling was done retrospectively from the patient's medical record data by calculating the minimum sample using the Finite Population Correction formula. The 115 patients were consisted of 83 women (72.2%) and 32 men (27.8%), the most common single therapy was metformin in range of 25 patients (21,7%) to 50 patients (43,5%)/month, followed by combination of metformin and gliclazide within range of 16 patients (13,9%) to 22 patients (19,1%)/month, and combination of metformin, gliquidone, and pioglitazone within range of 1 patient (0,9%) to 7 patients (6,1%)/month, and metformin, gliclazide, and acarbose between 3 patient (2,6%) to 6 patients (5,2%)/month. Other drugs for comorbidities mostly was hypertension drugs (57,2%).
Diabetes mellitus patients in Indonesia: management in a tertiary hospital compared to primary health care Hikmat Permana; Raspati Cundarani Koesoemadinata; Nanny Natalia Mulyani Soetedjo; Nury Fitria Dewi; Novi Jayanti; Sofia Imaculata; Rovina Ruslami; Bachti Alisjahbana; Susan Margaret McAllister
Universa Medicina Vol. 41 No. 2 (2022)
Publisher : Faculty of Medicine, Universitas Trisakti

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18051/UnivMed.2022.v41.157-168

Abstract

Background The increasing prevalence of diabetes mellitus (DM) requires that patients have greater access to care, which is yet lacking in many low- and middle-income countries and the quality of which varies between health care facilities. We compare the characteristics, complications, and risk profile of diabetes in patients receiving care in primary and tertiary level health facilities in Bandung, Indonesia. MethodsAdult DM patients were recruited from 25 community health centres (CHCs) and the outpatient clinic at one referral hospital. Key data collected and compared to national guidelines were DM history, treatment, complications, blood pressure, height, weight, and laboratory examinations on glycated haemoglobin (HbA1c), lipid profile, and creatinine. Data analysis was by chi-square test. ResultsOf the 809 DM patients (median age 59 years, 63% female, 98% type 2 DM), 318 (39%) were from CHCs and 491 (61%) from the hospital. Overall median HbA1c was 8.3%, with no difference between CHC and hospital patients. Only 32% of patients with HbA1c ≥10% were on insulin (CHCs 5.9%, hospital 42.9%), and only 18% of those on insulin had glycaemic control. Hypertension was common (CHCs 62%, hospital 51%, p<0.001), and only 44% of CHC and 34% of hospital patients received antihypertensive therapy. Among those with macrovascular complications, only 32% (CHCs) and 26% (hospital) were receiving aspirin. The numbers reaching the treatment targets were low for those on antihypertensives and lipid-lowering medications (80/251 and 11/105, respectively). ConclusionGlycaemic control and management of complications of DM patients at both health care levels need considerable improvement.
Pola Penggunaan Antidiabetes Oral Pasien Diabetes Melitus Tipe 2 di Bagian Penyakit Dalam RSUD Kota Bandung Tahun 2017 Kevin Jonathan; Kuswinarti; Nanny Natalia Mulyani Soetedjo
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.433

Abstract

DM merupakan penyakit kronis seumur hidup, tidak dapat disembuhkan namun dapat dikontrol dengan intervensi farmakologis, salah satunya antidiabetes oral. Penelitian ini bertujuan untuk mengetahui pola penggunaan antidiabetes oral pada pasien rawat jalan DM tipe 2 di bagian Penyakit Dalam RSUD Kota Bandung pada Januari – Desember 2017. Penelitian ini merupakan penelitian deskriptif dengan desain penelitian potong lintang setiap bulan. Pengambilan sampel secara retrospektif dari data rekam medis pasien dengan menghitung sampel minimal menggunakan rumus Finite Population Correction. Dari 115 sampel meliputi 83 (72,2%) perempuan dan 32 (27,8%) laki-laki, antidiabetes terbanyak berupa terapi tunggal metformin berkisar antara 25 pasien (21,7%) hingga 50 pasien (43,5%)/bulan, diikuti terapi kombinasi 2 antidiabetes metformin dan gliklazid berkisar antara 16 pasien (13,9%) hingga 22 pasein (19,1%)/bulan, dan terapi kombinasi 3 antidiabetes metformin, glikuidon, dan pioglitazon berkisar antara 1 pasien (0,9%) hingga 7 pasien (6,1%)/bulan serta metformin, gliklazid, dan akarbose sebanyak 3 pasien (2,6%) hingga 6 pasien (5,2%)/bulan. Obat lain untuk komorbid DMT2 yang terbanyak adalah obat hipertensi sebanyak 57,2%. DM is a chronic disease, controlled pharmacologically, using – among others - oral antidiabetic drugs. This study aims to determine the pattern of use of oral anti-diabetics in DM type 2 outpatients in the Internal Medicine Department of Bandung City Hospital in January - December 2017. This is a descriptive cross-sectional monthly study. Sampling was done retrospectively from the patient’s medical record data by calculating the minimum sample using the Finite Population Correction formula. The 115 patients were consisted of 83 women (72.2%) and 32 men (27.8%), the most common single therapy was metformin in range of 25 patients (21.7%) to 50 patients (43.5%)/month, followed by combination of metformin and gliclazide within range of 16 patients (13.9%) to 22 patients (19.1%)/month, and combination of metformin, gliquidone, and pioglitazone within range of 1 patient (0.9%) to 7 patients (6.1%)/month, and metformin, gliclazide, and acarbose between 3 patient (2.6%) to 6 patients (5.2%)/month. Other drugs for comorbidities mostly were hypertension drugs (57.2%).
Sindroma Sheehan dengan Hiponatremia Berulang, Miositis dan Amenorrhea Sekunder Luse Loe; Nanny Natalia Mulyani Soetedjo; Hikmat Permana
Majalah Kedokteran Indonesia Vol 71 No 4 (2021): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.71.4-2021-561

Abstract

Introduction: Sheehan syndrome may arise after giving birth, which is caused by reduced pituitary perfusion due to low blood pressure during or after parturition. It has varied and unspecific symptoms. Early diagnosis and treatment is important to prevent death. Case report: We reported a case of 39 years old female with recurring hyponatremia, myositis and secondary amenorrhea, which were consistent with sheehan syndrome.Discussion: Patient had history of severe postpartum bleeding. She presented with hyponatremia, hypokalemia, and hypokalemia. This electrolyte imbalance might be caused by anterior pituitary hormones deficit, possible posterior pituitary hormones deficit, disturbance of adrenocortical and estrogen hormone. Increased creatinine kinase showed myositis, and possibly caused by herbal medication or other condition.Conclusion: In this case, the patient was getting well after given adequate electrolyte and hormone replacement, without steroid administration.
Characteristics and Clinical Outcomes of COVID-19 Patients with Hyperglycemia: Retrospective Cohort Study from a COVID-19 Referral Hospital, Bandung, Indonesia Permana, Hikmat; Ikhsanawati, Annisa; Susandi, Evan; Soetedjo, Nanny Natalia Mulyani; Alisjahbana, Bachti
Althea Medical Journal Vol 10, No 4 (2023)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/amj.v10n4.3111

Abstract

Background: COVID-19 often causes severe complications in patients with metabolic disorders such as diabetes mellitus. Conversely, inflammation caused by infection may also trigger insulin resistance, resulting in hyperglycemia and is related to the disease severity. This study aimed to describe the characteristics and clinical outcomes of COVID-19 patients with hyperglycemia at one of the COVID-19 referral hospitals in Bandung, Indonesia.Methods: This retrospective cohort study used secondary data from medical records of COVID-19 patients admitted to Dr. Hasan Sadikin General Hospital Bandung, Indonesia from March 2020 to March 2021. This study included all patients with confirmed COVID-19, aged >18 years, and had at least one blood glucose test at admission. Patients were grouped based on three possible types of hyperglycemia, namely diabetes mellitus, reactive hyperglycemia, and steroid-induced hyperglycemia; then their characteristics and disease outcomes were compared. Results: This study identified 1,114 patients’ medical records and included 1,013 data in the analysis. Hyperglycemia occurred in 45.1% of COVID-19 patients. The most common hyperglycemia types were diabetes mellitus (55.7%), reactive hyperglycemia (37.4%), and steroid-induced hyperglycemia (7%). The steroid-induced hyperglycemia group had similar characteristics as the diabetes group. The reactive hyperglycemia group exhibited a metabolic syndrome pattern resembling pre-diabetic conditions. The highest rates of severe disease and mortality were seen in the steroid-induced hyperglycemia group, followed by the diabetes group.Conclusions: There is an elevated prevalence of hyperglycemia in COVID-19 patients with diabetes. The steroid-induced hyperglycemia group has the most unfavorable outcomes. These observations emphasize the importance of identifying hyperglycemic conditions to improve management and outcomes.
Pola Penggunaan Antidiabetes Oral Pasien Diabetes Melitus Tipe 2 di Bagian Penyakit Dalam RSUD Kota Bandung Tahun 2017 Kevin Jonathan; Kuswinarti; Nanny Natalia Mulyani Soetedjo
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.433

Abstract

DM merupakan penyakit kronis seumur hidup, tidak dapat disembuhkan namun dapat dikontrol dengan intervensi farmakologis, salah satunya antidiabetes oral. Penelitian ini bertujuan untuk mengetahui pola penggunaan antidiabetes oral pada pasien rawat jalan DM tipe 2 di bagian Penyakit Dalam RSUD Kota Bandung pada Januari – Desember 2017. Penelitian ini merupakan penelitian deskriptif dengan desain penelitian potong lintang setiap bulan. Pengambilan sampel secara retrospektif dari data rekam medis pasien dengan menghitung sampel minimal menggunakan rumus Finite Population Correction. Dari 115 sampel meliputi 83 (72,2%) perempuan dan 32 (27,8%) laki-laki, antidiabetes terbanyak berupa terapi tunggal metformin berkisar antara 25 pasien (21,7%) hingga 50 pasien (43,5%)/bulan, diikuti terapi kombinasi 2 antidiabetes metformin dan gliklazid berkisar antara 16 pasien (13,9%) hingga 22 pasein (19,1%)/bulan, dan terapi kombinasi 3 antidiabetes metformin, glikuidon, dan pioglitazon berkisar antara 1 pasien (0,9%) hingga 7 pasien (6,1%)/bulan serta metformin, gliklazid, dan akarbose sebanyak 3 pasien (2,6%) hingga 6 pasien (5,2%)/bulan. Obat lain untuk komorbid DMT2 yang terbanyak adalah obat hipertensi sebanyak 57,2%. DM is a chronic disease, controlled pharmacologically, using – among others - oral antidiabetic drugs. This study aims to determine the pattern of use of oral anti-diabetics in DM type 2 outpatients in the Internal Medicine Department of Bandung City Hospital in January - December 2017. This is a descriptive cross-sectional monthly study. Sampling was done retrospectively from the patient’s medical record data by calculating the minimum sample using the Finite Population Correction formula. The 115 patients were consisted of 83 women (72.2%) and 32 men (27.8%), the most common single therapy was metformin in range of 25 patients (21.7%) to 50 patients (43.5%)/month, followed by combination of metformin and gliclazide within range of 16 patients (13.9%) to 22 patients (19.1%)/month, and combination of metformin, gliquidone, and pioglitazone within range of 1 patient (0.9%) to 7 patients (6.1%)/month, and metformin, gliclazide, and acarbose between 3 patient (2.6%) to 6 patients (5.2%)/month. Other drugs for comorbidities mostly were hypertension drugs (57.2%).
Rhabdomyolysis in Thyroid Crisis Nanny Natalia Mulyani Soetedjo; Luse Loe; Maya Kusumawati; Ervita Ritonga; Hikmat Permana
Majalah Kedokteran Indonesia Vol 72 No 5 (2022): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.72.5-2022-829

Abstract

Introduction: Hyperthyroidism might lead to rhabdomyolysis. Rhabdomyolysis in thyroid crisis is very rare, currently there are only 7 cases in the world. This is the eight cases in the world that had been reported.Cases: We reported a case of a 46-year-old man with Graves’ Disease who presented with thyroid crisis and rhabdomyolysis.Discussion: The patient came with shortness of breath and palpitations for 10 hours before admission. Tachycardia, tachypnea, thyroid enlargement, motoric weakness, and bilateral lung crackles were noted. The Burch-Wartofsky Point Scale was 60 and the Japan Thyroid Association grade was TS2 first combination. Laboratory showed hyperkalemia (7.7 meq/L), increase in urea (144 mg/dl), creatinine (1.92 mg/dl), fT4 ( greater than 5.0), TSHs (0.06 uIU/ml) creatine kinase (3645 U/L), positive TRAb and Anti-TPO. The patient was treated with thyroid crisis management (propylthiouracil, lugol, dexamethasone) and supportive treatment (dobutamine, digoxin, furosemide, antibiotics, hyperkalemia therapy). After hospitalized for 11 days, the patient was discharged with resolution clinical symptom and levels of CK, urea, and creatinine. Conclusion: Hyperthyroidism might lead to rhabdomyolysis. This condition needs to be recognized and becomes a differential diagnosis in non-traumatic rhabdomyolysis accompanied by acute kidney injury. Therefore, can lead to appropriate and prompt management.
Co-Authors Annisa Ikhsanawati, Annisa Bachti Alisjahbana Hikmat Permana Hikmat Permana Hikmat Permana Hikmat Permana Kevin Jonathan Koesoemadinata, Raspati C. Kusumawati, Maya Kuswinarti Kuswinarti - Luse Loe Luse Loe Novi Jayanti Nury Fitria Dewi Ritonga, Ervita Rovina Ruslami, Rovina Sofia Imaculata Susan Margaret McAllister Susandi, Evan